A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION)

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This retrospective study will assess the sustained virologic response and the safety of two different interferons (pegylated or conventional) in patients with chronic hepatitis C. Data will be collected for 24 weeks.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Interferon-alpha; Interferons; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin

Criteria

Inclusion Criteria:

• Adult patients, >/=18 years and <70 years of age

• Diagnosis of hepatitis C

• Assessment of viral load prior to treatment (mandatory for genotype 1 only)

• Liver biopsy

• Co-morbidities data

• Use of interferon (pegylated or conventional) and ribavirin to treat hepatitis C infection genotype 2 and 3 and pegylated interferon plus ribavirin to treat hepatitis C infection genotype 1

• Above mentioned treatment started between 01-Sep-2007 and 31-Aug-2008

Exclusion Criteria:

• Co-infection with human immunodeficiency virus

• Co-infection with hepatitis B virus

• Presence of hepatocarcinoma

• Patients submitted to hemodialysis

• Organ transplant patients